| Literature DB >> 24159302 |
Caroline Borges Weiler1, Francielli Pantella Kunz de Jesus, Graziela Habib Nardi, Erico Silva Loreto, Janio Morais Santurio, Selene Dall'acqua Coutinho, Sydney Hartz Alves.
Abstract
Malassezia pachydermatis is associated with dermatomycoses and otomycosis in dogs and cats. This study compared the susceptibility of M. pachydermatis isolates from sick (G1) and healthy (G2) animals to azole and polyene antifungals using the M27-A3 protocol. Isolates from G1 animals were less sensitive to amphotericin B, nystatin, fluconazole, clotrimazole and miconazole.Entities:
Keywords: Malassezia pachydermatis; antifungal agents; susceptibility
Year: 2013 PMID: 24159302 PMCID: PMC3804196 DOI: 10.1590/S1517-83822013005000009
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Distribution of MICs (μg/mL) for M. pachydermatis isolated from ear canals of animals with and without otitis.
| Groups | No. (%) of isolates sensitive to concentrations of: | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 0.01 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1.0 | 2.0 | ||
| KTZ | G1 | 19 (47.5) | - | 3 (7.5) | 8 (20) | 2 (5) | 8 (20) | - | - |
| G2 | 17 (42.5) | 2 (5) | 5 (12.5) | 10 (25) | 4 (10) | 2 (5) | - | - | |
|
| |||||||||
| FLZ | G1 | 2 (5) | 2 (5) | 3 (7.5) | 9 (22.5) | 5 (12.5) | 15 (37.5) | 4 (10) | - |
| G2 | 3 (7.5) | 2 (5) | 2 (5) | 11 (27.5) | 5 (12.5) | 7 (17.5) | - | - | |
|
| |||||||||
| ITZ | G1 | 22 (55) | 2 (5) | 4 (10) | 5 (12.5) | 3 (7.5) | 4 (10) | - | - |
| G2 | 17 (42.5) | 3 (7.5) | 10 (25) | 9 (22.5) | 1 (2.5) | - | - | - | |
|
| |||||||||
| VRZ | G1 | 10 (25) | 10 (25) | 9 (22.5) | 7 (17.5) | 4 (10) | - | - | - |
| G2 | 16 (40) | 9 (22.5) | 6 (15) | 9 (22.5) | - | - | - | - | |
|
| |||||||||
| CTZ | G1 | 5 (12.5) | 4 (10) | 1 (2.5) | 7 (17.5) | 7 (17.5) | 12 (30) | 4 (10) | - |
| G2 | 6 (15) | 11 (27.5) | 4 (10) | 9 (22.5) | 5 (12.5) | 5 (12.5) | - | - | |
|
| |||||||||
| MCZ | G1 | 6 (15) | 6 (15) | 2 (5) | 4 (10) | 8 (20) | 14 (35) | - | - |
| G2 | 9 (22.5) | 10 (25) | 5 (12.5) | 5 (12.5) | 4 (10) | 7 (17.5) | - | - | |
|
| |||||||||
| NYS | G1 | 3 (7.5) | 6 (15) | 3 (7.5) | 5 (12.5) | 7 (17.5) | 11 (27.5) | 1 (2.5) | 4(10) |
| G2 | 7 (17.5) | 8 (20) | 5 (12.5) | 6 (15) | 5 (12.5) | 7 (17.5) | 2 (5) | - | |
|
| |||||||||
| AMB | G1 | 4 (10) | 4 (10) | 1 (2.5) | 7 (17.5) | 7 (17.5) | 13 (32.5) | 4 (10) | - |
| G2 | 12 (30) | 3 (7.5) | 2 (5) | 8 (20) | 3 (7.5) | 12 (30) | - | - | |
Ketoconazole,
Fluconazole,
Itraconazole,
Voriconazole,
Clotrimazole,
Miconazole,
Nystatin,
Amphotericin B.
G1: isolated from animals with otitis; G2: saprophytic isolates.
In vitro susceptibility of M. pachydermatis isolates to antifungal agents.
| Antifungal | Groups | MIC range | MIC50 | MIC90 | GM |
|---|---|---|---|---|---|
| Ketoconazole | G1 | 0.01–0.5 | 0.06 | 0.5 | 0.048 |
| G2 | 0.01–0.5 | 0.06 | 0.25 | 0.041 | |
|
| |||||
| Fluconazole | G1* | 0.01–1.0 | 0.25 | 0.5 | 0.219 |
| G2** | 0.01–0.5 | 0.125 | 0.5 | 0.068 | |
|
| |||||
| Itraconazole | G1 | 0.01–0.5 | 0.01 | 0.25 | 0.032 |
| G2 | 0.01–0.25 | 0.03 | 0.125 | 0.032 | |
|
| |||||
| Voriconazole | G1 | 0.01–0.25 | 0.03 | 0.125 | 0.042 |
| G2 | 0.01–0.125 | 0.03 | 0.125 | 0.029 | |
|
| |||||
| Clotrimazole | G1* | 0.01–1.0 | 0.25 | 0.5 | 0.163 |
| G2** | 0.01–0.5 | 0.06 | 0.5 | 0.069 | |
|
| |||||
| Miconazole | G1* | 0.01–0.5 | 0.25 | 0.5 | 0.124 |
| G2** | 0.01–0.5 | 0.06 | 0.5 | 0.061 | |
|
| |||||
| Nystatin | G1* | 0.01–2.0 | 0.25 | 1.0 | 0.181 |
| G2** | 0.01–1.0 | 0.06 | 0.5 | 0.084 | |
|
| |||||
| Amphotericin B | G1* | 0.01–1.0 | 0.25 | 0.5 | 0.180 |
| G2** | 0.01–0.5 | 0.125 | 0.5 | 0.081 | |
G1: isolated from animals with otitis; G2: saprophytic isolates;
Interval between the lowest and highest MICs;
Minimum concentration of the antifungal agent able to inhibit the growth of 50% of the isolates;
Minimum concentration of the antifungal agent able to inhibit the growth of 90% of the isolates;
Geometric mean of MICs. (*)(**)Statistically different susceptibility profiles (p < 0.05).